API Octreotide acetate powder / Octreotide CAS 83150-76-9

Name:Octreotide Acetate powder, Octreotide powder
CAS NO.: 83150-76-9
Molecular formula: C49H66N10O10S2
Molecular weight:1019.2393
Specification: >98%
Boilling point:1447.228°C at 760 mmHg

Function
Need long-term Octreotide Acetate treatment of acromegaly, such as postoperative residual tumor growth hormone to increase serum levels of growth hormone, pituitary after external beam radiotherapy has yet to reach full therapeutic serum growth hormone levels, some are not suitable for the surgical treatment and new diagnosis of growth hormone secretion adenomas in patients with preoperative treatment

Octreotide is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone,glucagon, and insulin than the natural hormone. It was first synthesized in 1979 by the chemist Wilfried Bauer.

Factory supply 99% cas 83150-76-9 Octreotide Acetate powder with low price in stock

English name: Octreotide Acetate powder, Octreotide powder
anothername:L-cysteinamide,D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl) propyl)-cyclic (2->7)-disulfide, (R-(R*,R*))

Synonyms:11: PN:US20030229017 PAGE: 13 claimed protein;14: PN: DE10147056 PAGE: 40 claimedprotein;17: PN: US6268342 SEQID: 18 claimed protein;1: PN: EP1118336 SEQID: 1claimed protein;1: PN: WO2005007122 TABLE: 22 claimed protein;25: PN:WO2007081792 SEQID: 40 claimed protein;2: PN: EP1358890 TABLE: A claimedprotein;Longastatin;L-Cysteinamide,D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2
Specification: 98%
CAS NO.: 83150-76-9
Molecular weight:1019.2393
Formula Weight: 1019.24
Molecular formula: C49H66N10O10S2
Boilling point:1447.228°C at 760 mmHg
The Food and Drug Administration (FDA) has approved the usage of a salt form of this peptide, octreotide acetate, as an injectable depot formulation for the treatment of acromegaly, gigantism, thyrotropinoma, diarrhea and flushing episodes associated with carcinoid syndrome, and diarrhea in patients with vasoactive intestinal peptide-secreting tumors (VIPomas).